A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease.

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

101 reported reactions of this kind linked to exenatide, three people died. 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked ...

A randomized controlled trial (RCT) evaluated whether vaporized nicotine products (VNPs) are more effective than nicotine replacement therapies (NRT) for smoking cessation among people experiencing ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects.

Exenatide has been linked to 101 cases, with three deaths. Dulaglutide and Lixisenatide, on the other hand, have been linked with 63 cases. No known deaths have been associated.

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials in the UK to launch a new study into side effects.Some cases of ...

Q: I’m trying to improve my nutrition, but it’s not easy. Can you help me feel more motivated, please? — Jenny T., Evanston, Ill.